Home・Lista de Ações・Ocular Therapeutix Inc

Ocular Therapeutix Inc

Fechado

SetorSaúde

10.64

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

10.59

Máximo

10.74

Indicadores-chave
By Trading Economics
Rendimento	9.8M -79M
Vendas	2.7M 13M
EPS	-0.35
Margem de lucro	-584.512
Funcionários	325
EBITDA	10M -74M

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+142.29% upside

Dividendos
By Acuity
Próximos Ganhos	3 de nov. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	383M 2.3B
Abertura anterior	10.64
Fecho anterior	10.64

Sentimento de Notícias

By Acuity

29%

71%

62 / 339 Ranking em Healthcare

Ocular Therapeutix Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

3 de set. de 2026, 20:01 UTC

Ocular Therapeutix Inc's shares are lower today, breaking a trend of higher closes since Wednesday. No specific news was identified to explain the decline.

2 de set. de 2026, 23:31 UTC

Ocular Therapeutix shares were roughly flat in after-market hours. The broader market reacted to a weaker-than-expected ADP payrolls report.

1 de set. de 2026, 19:46 UTC

Ocular Therapeutix Inc's shares are higher today, rebounding from earlier volatility and remaining well above the 20-day moving average.

31 de ago. de 2026, 21:01 UTC

Ocular Therapeutix Inc is trading higher in after-market hours, showing strength despite broader market pressure from hawkish Fed remarks. No specific news was identified.

28 de ago. de 2026, 20:08 UTC

Ocular Therapeutix Inc shares are lower today, reflecting broader market declines amid rising U.S. Treasury yields and inflation concerns. No specific company news was identified.

27 de ago. de 2026, 21:01 UTC

Ocular Therapeutix Inc shares are trading lower in after-market hours. No specific company news was identified to explain this movement.

26 de ago. de 2026, 19:36 UTC

Ocular Therapeutix Inc shares are lower today, with no specific news identified. This follows U.S. PCE data indicating inflationary pressures.

24 de ago. de 2026, 20:06 UTC

Social Media

Ocular Therapeutix Inc. shares are lower amid a lawsuit from EyePoint, Inc. and broader market pressures, despite a brief rebound earlier in the session.

22 de ago. de 2026, 00:02 UTC

Ocular Therapeutix Inc is trading higher in after-market hours, maintaining momentum from Friday's close amid a broadly positive market performance.

21 de ago. de 2026, 21:01 UTC

Ocular Therapeutix Inc shares are higher in after-market trading, reflecting strong performance amid positive sentiment in related sectors and developments in the cryptocurrency market.

20 de ago. de 2026, 20:02 UTC

Ocular Therapeutix Inc is lower today amid broader market declines following Walmart's disappointing sales growth and guidance, contributing to increased selling pressure.

19 de ago. de 2026, 23:21 UTC

Ocular Therapeutix Inc shows modest gains in after-market trading, with no specific news identified for the price movement. The stock remains above its 20-day moving average.

18 de ago. de 2026, 22:26 UTC

Social Media

Ocular Therapeutix shares rise in after-market hours after Cowen set a $20 price target, and Baird raised its target to $30 amid competitive advantages.

17 de ago. de 2026, 23:11 UTC

Ocular Therapeutix Inc's shares are higher in after-market trading, continuing a strong performance since Monday's close and reaching a notable high.

14 de ago. de 2026, 19:46 UTC

Ocular Therapeutix Inc shares are lower amid a decline in the Pharmaceuticals sub-sector. The stock has traded down since Thursday's close.

13 de ago. de 2026, 23:16 UTC

Ocular Therapeutix Inc's shares are lower in after-market hours, reflecting a slight decline since Thursday's close. No specific news was identified for this movement.

12 de ago. de 2026, 20:01 UTC

Ocular Therapeutix Inc shares are higher in Wednesday's session, with elevated trading volume. The stock remains above its 20-day moving average.

11 de ago. de 2026, 23:21 UTC

Ocular Therapeutix Inc shares fell during after-market hours, reaching a session low before slightly recovering. Broader market dynamics may be influencing this decline.

10 de ago. de 2026, 20:06 UTC

Ocular Therapeutix Inc is trading higher, recovering above its 20-day moving average amid a broader trend of three consecutive sessions finishing higher.

7 de ago. de 2026, 21:01 UTC

Ocular Therapeutix Inc shares are higher in after-market hours, continuing an upward trend after three consecutive sessions of gains.

6 de ago. de 2026, 20:06 UTC

Ocular Therapeutix Inc shares are higher during Thursday's session, recovering from an earlier dip despite trading below their 20-day moving average.

5 de ago. de 2026, 21:03 UTC

Ocular Therapeutix Inc shares are lower in after-market trading, with no specific news identified to explain the decline. The stock remains under pressure.

3 de ago. de 2026, 20:06 UTC

Social Media

News

Ocular Therapeutix shares rise after reporting Q2 revenue of $13.5 million, exceeding estimates, and announcing plans for a new drug application for AXPAXLI.

31 de jul. de 2026, 21:01 UTC

Ocular Therapeutix Inc shares are lower in after-market hours with no specific news identified. Broader market conditions reflect mixed performance amid rising inflation concerns.

30 de jul. de 2026, 19:39 UTC

Ocular Therapeutix shares are higher today, continuing an upward trend since Wednesday. The U.S. Dollar Index decline may be influencing broader market dynamics.

28 de jul. de 2026, 19:06 UTC

News

Ocular Therapeutix shares are lower amid broader market volatility and regulatory challenges, reaching a session low earlier today.

27 de jul. de 2026, 21:01 UTC

Ocular Therapeutix Inc. shares are higher in after-market trading, reaching a peak shortly after the session began amid improved European market sentiment.

22 de jul. de 2026, 18:36 UTC

Social Media

Ocular Therapeutix is presenting at the HC Wainwright conference, but shares are declining and remain below their 20-day moving average.

21 de jul. de 2026, 23:41 UTC

Ocular Therapeutix Inc shares rose in after-market trading, reaching their highest cumulative return of the day. The stock remains below its 20-day moving average.

20 de jul. de 2026, 19:46 UTC

Social Media

Ocular Therapeutix shares are lower today, continuing a downward trend. Early gains were followed by a pullback amid uncertain investor sentiment.

Comparação entre Pares

Variação de preço

Ocular Therapeutix Inc Previsão

Preço-alvo

By TipRanks

142.29% parte superior

Previsão para 12 meses

Média 25.78 USD 142.29%

Máximo 31 USD

Mínimo 18 USD

Com base em 10 analistas de Wall Street que oferecem metas de preço de 12 meses para Ocular Therapeutix Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

10 ratings

Comprar

Manter

Vender

Com base em 10 analistas que deram avaliações de ações para Ocular Therapeutix Inc - Dist nos últimos 3 meses.

Sentimento

By Acuity

62 / 339 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Ocular Therapeutix Inc

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.